NEJM: Adalimumab and MTX Effective in JIA Uveitis Save
The NEJM has published the results of a randomized, placebo-controlled trial showing adalimumab (ADA) and methotrexate (MTX) is effective in reducing ocular flares in juvenile idiopathic arthritis (JIA) with uveitis. (Citation source: http://buff.ly/2qrZa1g)
The results of the study were so convincing that the data safety monitoring committee had to prematurely halt the study, given the obvious benefits of ADA and MTX compared to those on placebo.
Although they planned to enroll 114 patients, the results are based on 90 children with JIA-associated uveitis, all of whom were taking MTX. Patients were randomized 2:1 to either ADA or placebo and followed for 2 years or until treatment failure (prespecified increase in ocular inflammation).
Treatment failures were significantly less prevalent (27%) in the ADA group compared to those on placebo (60%) (P<0.0001).
Adverse events and serious adverse events were more frequent with ADA.
ADD THE FIRST COMMENT
Disclosures
The author has received compensation as an advisor or consultant on this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.